Preview

Современная ревматология

Расширенный поиск

Эторикоксиб в лечении ревматическихЗаболеваний

https://doi.org/10.14412/1996-7012-2010-592

Полный текст:

Аннотация

Эторикоксиб - селективный ингибитор ЦОГ 2 нового поколения. Недавно он был лицензирован в России для лечения остеоартроза (ОА), ревматоидного артрита (РА), анкилозирующего спондилита (АС) и острого подагрического артрита. Препарат выпускается в таблетках по 60, 90 и 120 мг. Его назначают 1 раз в сутки. Он применяется для длительной терапии ОА в дозе 60 мг/сут,
РА - по 90 мг/сут, для купирования острого подагрического артрита - в дозе 120 мг/сут (не более 8 дней). Высокая эффективность и хорошая переносимость эторикоксиба доказаны в целом ряде клинических исследований, и в настоящее время препарат
широко применяется в лечении ОА, РА, АС и острого подагрического артрита. Его также с успехом используют при боли в нижней части спины и дисменорее. В ряде клинических исследований было показано, что эторикоксиб отличается хорошей переносимостью, существенно повышает качество жизни больных и может с успехом использоваться для длительной терапии ревматических заболеваний. При этом он вызывает значительно меньше нежелательных явлений со стороны желудочно-кишечного тракта, чем неселективные нестероидные противовоспалительные препараты.

Литература

1. <div><p>Mamdani M., Rochon P.A., Juurlink D.N. et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 2002 Sep 21;325(7365):624.</p><p>Friesen R.W., Brideau C., Chan C.C. et al. 2-Pyridinyl-3-(4- methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett 1998 Oct 6;8(19):2777-82.</p><p>Patrignani P., Capone M.L., Tacconelli S. Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. Expert Opin Pharmacother 2003 Feb;4(2):265-84.</p><p>Riendeau D., Percival M.D., Brideau C. et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001 Feb;296(2):558-66.</p><p>Agrawal N.G., Porras A.G., Matthews C.Z. et al. Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. J Clin Pharmacol 2003 Mar;43(3):268-76.</p><p>Agrawal N.G., Rose M.J., Matthews C.Z. et al. Pharmacokinetics of etoricoxib in patients with hepatic impairment. J Clin Pharmacol 2003 Oct;43(10):1136-48.</p><p>Curtis S.P., Ng J., Yu Q. et al. Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. Clin Ther 2004 Jan;26(1):70-83.</p><p>Zerbini C., Ozturk Z.E., Grifka J. et al. Etoricoxib CLBP Study Group. Efficacy of etoricoxib 60 mg/day and diclofenac 150 mg/day in reduction of pain and disability in patients with chronic low back pain: results of a 4-week, multinational, randomized, double- blind study. Curr Med Res Opin 2005 Dec;21(12):2037-49. 9. Nor Azlin M.I., Maryasalwati I.,</p><p>Norzilawati M.N. et al. The efficacy of etoricoxib vs mefenamic acid in the treatment of primary dysmenorrhoea: a randomised comparative trial. J Obstet Gynaecol 2008 May;28(4):424-6</p><p>Gottesdiener K., Schnitzer T., Fisher C. et al. Protocol 007 Study Group. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology (Oxford) 2002 Sep;41(9):1052-61.</p><p>Zacher J., Feldman D., Gerli R. et al. Etoricoxib OA study group. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. Curr Med Res Opin 2003;19(8):725-36.</p><p>Reginster J.Y., Malmstrom K., Mehta A. et al. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis 2007 Jul;66(7):945-51.</p><p>Hunsche E., Geling O., Kong S.X. et al. Impact of etoricoxib, a novel COX-2 inhibitor, on social and emotional quality of life of patients with osteoarthritis. Osteoporosis Int 2002;13:S20.</p><p>Curtis S.P., Maldonado-Cocco J., Losada B.R. et al. Treatment with etoricoxib (MK- 0663), a COX-2-selective inhibitor, resulted in maintenance of clinical improvement in rheumatoid arthritis [abstract]. Annual Meeting of the European League Against Rheumatism, 13-16 June 2001, Prague, Czech Republic. FRI0030.</p><p>Curtis S.P., Losada B., Bosi-Ferraz M. et al. 2003a. Etoricoxib and diclofenac demonstrate similar efficacy in a 174-week randomized study of rheumatoid arthritis patients [poster]. American College of Rheumatology 67th Annual Scientific Meeting, 23-28 October 2003, Orlando, FL, USA: 213.</p><p>Matsumoto A.K., Melian A., Mandel D.R. et al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol 2002;29:1623-30.</p><p>Matsumoto A.K., Zhao P.L., Cichanowitz N. et al. Etoricoxib is efficacious in patients with rheumatoid arthritis (RA) on concomitant therapy with disease modifying antirheumatic drugs (DMARDs), and/or low-dose corticosteroids [poster]. American College of Rheumatology 67th Annual Scientific Meeting, 23-28 October 2003, Orlando, FL, USA: 209.</p><p>Collantes E., Curtis S.P. Lee K.W. et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]. BMC Fam Pract 2002;3:10.</p><p>Schumacher H.R., Jr., Boice J.A., Daikh D.I. et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ 2002;324:1488-92.</p><p>Rubin B.R., Burton R., Navarra S. et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthr Rheum 2004;50:598-606. 21. Van der Heijde D., Baraf H.S., Ramos-</p><p>Remus C. et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fiftytwo-week, randomized, controlled study. Arthr Rheum 2005;52:1205-15.</p><p>Gossec L., van der Heijde D., Melian A. et al. The efficacy of cyclooxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann Rheum Dis 2005;64:1563-7.</p><p>Jarrett S.J., Mcgonagle D., Marzo-Ortega H. et al. Etoricoxib reduces the need for biologic therapy in ankylosing spondylitis (AS) but has no effect on magnetic resonance imaging. Results from an open study [abstract]. American College of Rheumatology 68th Annual Scientific Meeting, 16-21 October 2004, San Antonio, TX, USA: 1634.</p><p>Birbara C.A., Puopolo A.D., Munoz D.R. et al. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability - a randomized, placebocontrolled, 3-month trial. J Pain 2003;4:307-15.</p><p>Pallay R.M., Seger W., Adler J.L. et al. Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial. Scand J Rheumatol 2004;33:257-66.</p><p>Hernandez-Garduno A., Vazquez-Leduc A., Querol-Vinagre J.V. et al. Clinical evaluation following treatment with etoricoxib (60, 90 and 120 mg once a day) in patients with acute low back pain: a cohort, open, nonrandomized, multicenter study [abstract]. Ann Rheum Dis 2005;64(Suppl. III):521.</p><p>Zerbini C., Ozturk Z.E., Grifka J. et al. Efficacy of etoricoxib 60 mg/day and diclofenac 150 mg/day in reduction of pain and disability in patients with chronic low back pain: results of a 4-week, multinational, randomized, double-blind study. Curr Med Res Opin 2005;21:2037-49.</p><p>Rasmussen G.L., Bourne M.H., Rhondeau S.M. et al. Etoricoxib provides pain relief and reduces opioid use in postorthopedic surgery patients [poster]. Annual European Congress of Rheumatology, 9-12 June 2004, Berlin, Germany. SAT0130.</p><p>Malmstrom K., Kotey P., Cichanowitz N. et al. Analgesic efficacy of etoricoxib in primary dysmenorrhea: results of a randomized, controlled trial. Gynecol Obstet Invest 2003;56:65-9.</p><p>Ramos-Remus C.R., Hunsche E., Mavros P. et al. Evaluation of quality of life following treatment with etoricoxib in patients with arthritis or low-back pain: an open label, uncontrolled pilot study in Mexico. Curr Med Res Opin 2004;20:691-8.</p><p>Leung A.T., Malmstrom K., Gallacher A.E. et al. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin 2002;18:49-58.</p><p>Baraf H.S., Fuentealba C., Greenwald M. et al. EDGE Study Group. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial. J Rheumatol 2007 Feb;34(2):408-20.</p><p>Hunt R.H., Harper S., Watson D.J. et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003;98:1725-33.</p><p>Ramey D.R., Watson D.J., Yu C. et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib versus. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin 2005;21:715-22.</p><p>Watson D.J., Bolognese J.A., Yu C. et al. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs. Curr Med Res Opin 2004;20:1899-908.</p><p>Cannon C.P., Curtis S.P., FitzGerald G.A. et al. MEDAL Steering Committee. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Longterm (MEDAL) programme: a randomised comparison. Lancet 2006 Nov 18;368(9549):1771-81.</p></div><br />


Для цитирования:


Олюнин Ю.А., Олюнин Ю.А. Эторикоксиб в лечении ревматическихЗаболеваний. Современная ревматология. 2010;4(1):75-79. https://doi.org/10.14412/1996-7012-2010-592

For citation:


Olyunin Yu.A., Olyunin Yu.A. ETHORICOXIB IN THE TREATMENT OF RHEUMATIC DISEASES. Modern Rheumatology Journal. 2010;4(1):75-79. (In Russ.) https://doi.org/10.14412/1996-7012-2010-592

Просмотров: 682


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)